| HOME >> BIOLOGY >> TECHNOLOGY |
Since 2006, Philips has been leading Bayer's U.S. oncology operations following the integration of the U.S. oncology businesses from Berlex and Bayer. In this capacity, he oversaw the U.S. oncology operations with sales of $350 million and a staff of over 150. In this position Philips was also either a member, or chair, of alliance executive committees which included Onyx, Novartis, Genzyme, and Favrille.
Prior to his current role, since 2004, Philips was the head of Berlex Oncology as Vice President and General Manager at Berlex Oncology. He was responsible for the U.S. oncology operations with sales of over $160 million. Prior to Berlex, Philips was with Schering Plough in U.S., global, and international roles. He began his career with Bristol Myers, where he worked in a variety of therapy areas including oncology, cardiology, and CNS.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.
This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of Zevalin, XYOTAX,
pixantrone and brostallicin include risks associated with preclinical and
clinical developments in the biopharmaceutical industry in general and with
Zevalin, XYOTAX, pixantrone and brostallicin in particular including,
without limitation, the ability of the Company to continue to raise capital
to fund its ongoing operations, the inability of the Company to
successfully obtain
'/>"/>
| SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |